What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Gene
Tom F. Lue mainly investigates Erectile dysfunction, Internal medicine, Endocrinology, Surgery and Penis.
Tom F. Lue has included themes like Chemotherapy, Urology, Neurotrophic factors, Sildenafil and Pathophysiology in his Erectile dysfunction study.
His research in Internal medicine intersects with topics in Diabetes mellitus, Hyperlipidemia and Nerve injury.
His Endocrinology research incorporates elements of Vascular endothelial growth factor and Stem cell.
His research investigates the link between Surgery and topics such as MEDLINE that cross with problems in Family medicine.
His study in Penis is interdisciplinary in nature, drawing from both Papaverine and Neurovascular bundle.
His most cited work include:
- Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. (1772 citations)
- Summary of the recommendations on sexual dysfunctions in men (879 citations)
- Oral Sildenafil in the Treatment of Erectile Dysfunction (749 citations)
What are the main themes of his work throughout his whole career to date?
Tom F. Lue mainly focuses on Erectile dysfunction, Internal medicine, Surgery, Endocrinology and Penis.
His work is dedicated to discovering how Erectile dysfunction, Stem cell are connected with Mesenchymal stem cell and other disciplines.
His Internal medicine research includes themes of Diabetes mellitus and Cardiology.
His Endocrinology research is multidisciplinary, incorporating perspectives in Neurotrophic factors and Vascular endothelial growth factor.
His work deals with themes such as Papaverine, Anesthesia and Blood flow, which intersect with Penis.
His Peyronie's disease research integrates issues from Deformity and Tunica albuginea.
He most often published in these fields:
- Erectile dysfunction (27.98%)
- Internal medicine (26.69%)
- Surgery (23.53%)
What were the highlights of his more recent work (between 2011-2021)?
- Erectile dysfunction (27.98%)
- Stem cell (11.05%)
- Surgery (23.53%)
In recent papers he was focusing on the following fields of study:
Tom F. Lue spends much of his time researching Erectile dysfunction, Stem cell, Surgery, Pathology and Urology.
His Erectile dysfunction study necessitates a more in-depth grasp of Internal medicine.
His studies in Stem cell integrate themes in fields like Adipose tissue and Bone marrow.
Surgery is closely attributed to Prostatectomy in his study.
His Pathology research is multidisciplinary, incorporating elements of CD34, Stem cell marker and Stem cell transplantation for articular cartilage repair.
His study on Urinary incontinence, Urethra and Cystometry is often connected to Intensity as part of broader study in Urology.
Between 2011 and 2021, his most popular works were:
- Is CD34 truly a negative marker for mesenchymal stromal cells (140 citations)
- Allogeneic and Xenogeneic Transplantation of Adipose-Derived Stem Cells in Immunocompetent Recipients Without Immunosuppressants (139 citations)
- Effects of Low‐Energy Shockwave Therapy on the Erectile Function and Tissue of a Diabetic Rat Model (124 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Gene
His primary scientific interests are in Stem cell, Erectile dysfunction, Pathology, Adipose tissue and Internal medicine.
His Stem cell study combines topics in areas such as Mesenchymal stem cell, Bone marrow and Transplantation.
His Erectile dysfunction study is concerned with Surgery in general.
Tom F. Lue focuses mostly in the field of Pathology, narrowing it down to matters related to Stem cell marker and, in some cases, Immunostaining.
His Adipose tissue study incorporates themes from Immunohistochemistry, Stromal cell, Paracrine signalling and Saline.
His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology, Urinary incontinence and Gene.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
